LLY
Eli Lilly and Company
LLY has the edge over YCBD overall, supported by stronger fundamentals and lower modeled downside.
YCBD
cbdMD, Inc.
YCBD's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
YCBD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Strong |
YCBD's revenue and balance sheet are currently healthy, but its profitability and cash flow are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
YCBD PE Valuation
YCBD has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
YCBD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect YCBD's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus YCBD down 100%.
YCBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$71.92 | +$66.48 |
| Q1 2024 | -$80.00 | +$247.12 |
| Q4 2023 | -$83.12 | +$266.08 |
| Q3 2023 | -$106.56 | +$339.84 |
| Q2 2023 | -$138.40 | +$246.80 |
| Q1 2023 | -$327.12 | -$147.12 |
| Q4 2022 | -$349.20 | -$118.80 |
| Q3 2022 | -$446.40 | -$277.20 |
YCBD lost $0.40 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over YCBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over YCBD on profitability, with a higher operating margin.
YCBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.6M | +21% |
| Q1 2026 | $5.6M | +19% |
| Q4 2025 | $5M | -1.9% |
| Q3 2025 | $4.7M | +3.6% |
| Q2 2025 | $4.6M | -11% |
| Q1 2025 | $4.7M | +8.5% |
| Q4 2024 | $5.1M | -4.9% |
| Q3 2024 | $4.6M | -20% |
YCBD's revenue is recovering but still below its 2020 peak: $6M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -20% | -0.7 points |
| Q1 2026 | -14% | -4 points |
| Q4 2025 | -5.7% | -4 points |
| Q3 2025 | -15% | -7.6 points |
| Q2 2025 | -20% | -12 points |
| Q1 2025 | -10% | +25 points |
| Q4 2024 | -1.7% | +18 points |
| Q3 2024 | -7% | +260 points |
YCBD's operating margin was −20% last quarter, down 0.7 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over YCBD on cash generation, producing positive trailing cash flow while its opponent burns cash.
YCBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$460.2K | +$245.5K |
| Q3 2025 | -$243.6K | -255% |
| Q2 2025 | -$705.7K | -344% |
| Q3 2024 | $157.4K | +$541.1K |
| Q2 2024 | $289.8K | +$632.7K |
| Q1 2024 | -$699.4K | +$931.8K |
| Q4 2023 | -$290.5K | +$2M |
| Q3 2023 | -$383.7K | +$1.8M |
YCBD has burned cash in most quarters: −$2M over the past year, against −$957,967 the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over YCBD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
YCBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +173K shares |
| 1 year | +1264% | +9.8M shares |
| 3 years | +6297% | +10.5M shares |
| 5 years | +10137% | +10.5M shares |
YCBD has 11M diluted shares, up 1264% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
YCBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | -0.4x | Net Cash |
| Q1 2020 | -1.6x | Net Cash |
YCBD has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
YCBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
YCBD's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
YCBD PE vs Healthcare Sector
YCBD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over YCBD on trend strength, trading above more of its moving averages.
YCBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.40 | 2.5% below |
| 20 week MA | $0.49 | 20% below |
| 50 week MA | $0.73 | 47% below |
| 100 week MA | $1.23 | 68% below |
| 200 week MA | $9.57 | 96% below |
YCBD is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over YCBD on returns for 2026, with the stronger performance.
YCBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $932.4 | $1,123.2 | +20% |
| 2021 | $1,123.2 | $406.8 | -64% |
| 2022 | $406.8 | $90.0 | -78% |
| 2023 | $90.0 | $8.32 | -91% |
| 2024 | $8.32 | $3.02 | -64% |
| 2025 | $3.02 | $1.68 | -44% |
| 2026 YTD | $1.68 | $0.39 | -77% |
YCBD has finished five years in a row lower, and it's down 77% so far in 2026.